Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Intra-Cellular Therapies Inc.'s Shares Had a Greater Than 30% Intraday Swing

By Sean Williams - Mar 1, 2017 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

From down 20% to up 13%, this pipeline update has investors on edge.

What happened

Shares of Intra-Cellular Therapies (ITCI -2.75%), a clinical-stage biopharmaceutical company focused on the development of medicines to treat disorders of the central nervous system, were taken for a wild ride on Wednesday. After falling by as much as 20% in early-morning trading, Intra-Cellular Therapies moved up by as much as 13% toward the end of the day. The reason for its volatility can be traced to its fourth-quarter earnings release.

So what

For the fourth quarter, Intra-Cellular Therapies reported a net loss of $27.5 million, or $0.64 per share, which was slightly narrower than the $28.8 million loss, or $0.67 per share, that it announced in Q4 2015. The difference can be tied to a modest reduction in research and development (R&D) expenses to $21.2 million from $22.9 million. R&D costs fell, because the second phase 3 trial with lumateperone (formerly ITI-007) as a treatment for schizophrenia ended in the third quarter. Intra-Cellular's net loss wound up coming in $0.13 narrower than Wall Street had forecast.

Lab researcher examining test tubes

Image source: Getty Images.

However, its net loss wasn't the big market mover. Clinical-stage biotech losses are notoriously hard to pinpoint, meaning the "beat" isn't really what investors were focused on. Instead, it was the corporate-pipeline update that sparked the waves of trading throughout the day.

The big update involved the announcement of a meeting with the Food and Drug Administration later this month to discuss the submission of a new drug application for lumateperone. For those who may not recall, Intra-Cellular's stock nosedived nearly 70% in one day back in September, after phase 3 results failed to show a statistically significant response in schizophrenia relative to the placebo. However, the company contends that it's not uncommon to see high placebo response rates, so it is pursuing a path forward for its experimental schizophrenia drug.

Additionally, Intra-Cellular announced the further development of its PDE-inhibitor program, with the expectation of initiating a phase 1/2 study involving ITI-214 in patients with Parkinson's disease within the next four months.

Doctor discussing results with female patient

Image source: Getty Images.

Now what

Today's excitement clearly revolves around the potential for a path forward for lumateperone, as well as the expectation of knowing whether there's a future for the drug as a schizophrenia treatment by the end of the month at the latest. The drug's safety and tolerability have never been in question. The major uncertainty is whether the FDA will accept data that didn't meet the primary endpoint of the study for approval consideration.

Though Intra-Cellular Therapies does have a number of ongoing clinical and preclinical trials, its schizophrenia program is by far its furthest along. If there winds up being no path forward in schizophrenia, it would be a notable setback for the company, and likely push out the time frame in which it would have the opportunity to bring an approved drug to market.

For the time being, my suggestion would be stick firmly to the sidelines.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intra-Cellular Therapies, Inc. Stock Quote
Intra-Cellular Therapies, Inc.
$55.62 (-2.75%) $-1.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.